CHAIRMAN OF THE BOARD AND CEO, Director이사회 의장 및 최고경영자(CEO), 이사
Auto-generated 2026-09-20 · not checked by a person · rebuilt weekly from EDGAR2026-09-20 자동 생성 · 사람이 검토하지 않음 · 매주 EDGAR에서 재생성Proxy (verbatim): “appointed Robert Michael as AbbVie’s CEO in July 2024 and as the Board’s Chairman in July 2025, succeeding Richard Gonzalez”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“2024년 7월 로버트 마이클을 애브비(AbbVie)의 CEO로, 2025년 7월에는 이사회 의장으로 임명하여 리처드 곤잘레스의 뒤를 이었다”원문appointed Robert Michael as AbbVie’s CEO in July 2024 and as the Board’s Chairman in July 2025, succeeding Richard Gonzalez
Proxy (verbatim): “Dr. Robert J. Alpern, a current Class II director, recently turned 75. Consistent with AbbVie’s governance guidelines, Dr. Alpern will not stand for re-election as a director as of the 2026 annual stockholder meeting and the board size will be reduced to twelve directors.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“현재 제2부 이사로 재직 중인 로버트 J. 알퍼른 박사가 최근 75세를 맞이했습니다. 애브비의 지배구조 지침에 따라, 알퍼른 박사는 2026년 정기 주주총회를 기점으로 이사 재선출에 출마하지 않을 예정이며, 이사회 규모는 12명으로 축소될 것입니다.”원문Dr. Robert J. Alpern, a current Class II director, recently turned 75. Consistent with AbbVie’s governance guidelines, Dr. Alpern will not stand for re-election as a director as of the 2026 annual stockholder meeting and the board size will be reduced to twelve directors.
Proxy (verbatim): “Mr. Michael is AbbVie’s Chairman and Chief Executive Officer, a position he has held since July 2025. Mr. Michael previously served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, where he was responsible for global commercial operations, finance, corporate human resources, global operations, business development and corporate strategy for the company. He previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“마이클 씨는 2025년 7월부터 애브비(AbbVie)의 회장 겸 최고경영자(CEO)를 맡고 있습니다. 마이클 씨는 2024년부터 최고경영자(CEO)를 역임했으며, 2023년 7월부터 2024년 6월까지는 사장 겸 최고운영책임자(COO)로 재직하며 회사의 글로벌 상업 운영, 재무, 기업 인사, 글로벌 운영, 사업 개발 및 기업 전략을 총괄했습니다. 그 이전에는 2022년 6월부터 2023년 7월까지 부회장 겸 사장을, 2021년 6월부터 [...]까지는 부회장 겸 재무 및 상업 운영 총괄이자 최고재무책임자(CFO)를 역임했습니다.”원문Mr. Michael is AbbVie’s Chairman and Chief Executive Officer, a position he has held since July 2025. Mr. Michael previously served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, where he was responsible for global commercial operations, finance, corporate human resources, global operations, business development and corporate strategy for the company. He previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to [...]
Proxy (verbatim): “· As a result of his numerous leadership roles across a more than 30-year career at Abbott and AbbVie, Mr. Michael has developed valuable business, strategic, leadership, and financial experience, as well as extensive knowledge of AbbVie and its complex global operations. Mr. Michael’s experience and knowledge enable him to contribute to AbbVie’s Board key insights into strategic, operations, business development, management, and financial matters.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“· 애보트(Abbott)와 애브비(AbbVie)에서 30년 이상 근무하며 다양한 리더십 직책을 역임한 결과, 마이클 씨는 귀중한 비즈니스, 전략, 리더십 및 재무 경험을 쌓았을 뿐만 아니라, 애브비와 그 복잡한 글로벌 운영에 대한 폭넓은 지식을 갖추게 되었습니다. 마이클 씨의 경험과 지식을 바탕으로, 그는 애브비 이사회에 전략, 운영, 사업 개발, 경영 및 재무 문제에 대한 핵심적인 통찰력을 제공할 수 있습니다.”원문· As a result of his numerous leadership roles across a more than 30-year career at Abbott and AbbVie, Mr. Michael has developed valuable business, strategic, leadership, and financial experience, as well as extensive knowledge of AbbVie and its complex global operations. Mr. Michael’s experience and knowledge enable him to contribute to AbbVie’s Board key insights into strategic, operations, business development, management, and financial matters.
Proxy (verbatim): “As announced on February 14, 2025, Mr. Michael, AbbVie’s Chief Executive Officer, became Chairman of the Board effective July 1, 2025. The Board has determined that this leadership structure, in which the offices of Chairman of the Board and Chief Executive Officer are held by one individual with a Board appointed Lead Independent Director, ensures the appropriate level of oversight, independence, and responsibility is applied to all Board decisions, including risk oversight, and is in the best interests of AbbVie and its stockholders. The Lead Independent Director is chosen annually by and fr [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“2025년 2월 14일에 발표된 바와 같이, 애브비(AbbVie)의 최고경영자(CEO)인 마이클 씨는 2025년 7월 1일부로 이사회 의장에 취임했습니다. 이사회는 이사회 의장직과 최고경영자(CEO)직을 한 사람이 겸임하고, 이사회가 선임한 수석 독립 이사가 함께하는 이러한 리더십 구조가 위험 감독을 포함한 모든 이사회 결정에 적절한 수준의 감독, 독립성 및 책임이 적용되도록 보장하며, 이는 애브비와 그 주주들의 최선의 이익에 부합한다고 판단했습니다. 수석 독립 이사는 매년 [...]에 의해 선출되며 [...]”원문As announced on February 14, 2025, Mr. Michael, AbbVie’s Chief Executive Officer, became Chairman of the Board effective July 1, 2025. The Board has determined that this leadership structure, in which the offices of Chairman of the Board and Chief Executive Officer are held by one individual with a Board appointed Lead Independent Director, ensures the appropriate level of oversight, independence, and responsibility is applied to all Board decisions, including risk oversight, and is in the best interests of AbbVie and its stockholders. The Lead Independent Director is chosen annually by and fr [...]
Proxy (verbatim): “The executive committee members are Mr. Michael, chair, Ms. Austin, Mr. Freyman, Mr. Hart, Ms. Meyer, and Mr. Waddell. This committee may exercise all of the authority of the Board in the management of AbbVie, except for matters expressly reserved by law for Board action.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“집행위원회 위원으로는 위원장인 마이클 씨, 오스틴 씨, 프레이먼 씨, 하트 씨, 마이어 씨, 그리고 와델 씨가 있습니다. 이 위원회는 법률에 의해 이사회가 처리하도록 명시적으로 규정된 사안을 제외하고, 애브비(AbbVie)의 경영에 있어 이사회의 모든 권한을 행사할 수 있습니다.”원문The executive committee members are Mr. Michael, chair, Ms. Austin, Mr. Freyman, Mr. Hart, Ms. Meyer, and Mr. Waddell. This committee may exercise all of the authority of the Board in the management of AbbVie, except for matters expressly reserved by law for Board action.
Proxy (verbatim): “● Robert A. Michael: Execute key strategic initiatives to drive sustainable long-term business performance; deliver value to our stockholders; build investor confidence and credibility; successfully advance mid- and late-stage pipeline assets; continue to drive employee engagement and motivation around AbbVie’s mission and future prospects; advance our transformation to a biopharmaceutical culture; and achieve proprietary pharmaceutical pipeline enhancement objectives.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“● 로버트 A. 마이클: 지속 가능한 장기적인 사업 성과를 이끌어내기 위해 핵심 전략 이니셔티브를 실행하고, 주주들에게 가치를 제공하며, 투자자의 신뢰와 신뢰성을 구축하고, 중·후기 단계의 파이프라인 자산을 성공적으로 발전시키며, 애브비(AbbVie)의 사명과 미래 전망을 중심으로 직원들의 참여와 동기를 지속적으로 고취하고, 바이오의약품 중심의 기업 문화로의 전환을 추진하며, 독자적인 의약품 파이프라인 강화 목표를 달성하는 것입니다.”원문● Robert A. Michael: Execute key strategic initiatives to drive sustainable long-term business performance; deliver value to our stockholders; build investor confidence and credibility; successfully advance mid- and late-stage pipeline assets; continue to drive employee engagement and motivation around AbbVie’s mission and future prospects; advance our transformation to a biopharmaceutical culture; and achieve proprietary pharmaceutical pipeline enhancement objectives.
Proxy (verbatim): “The increase in Mr. Michael’s change in pension value from 2024 to 2025, as shown in footnote (4), is primarily due to the following: (1) Mr. Michael’s pay adjustments in recognition of his new responsibilities as Chairman and CEO, which resulted in an increase in his 5-year final average earnings under the benefit formulas, and (2) Mr. Michael turning age 55 in 2025, which resulted in a one-time increase in the present value of his subsidized early retirement benefits payable for service after 2003, since upon reaching that milestone his benefit is actuarially reduced from age 62 under the Pe [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“각주 (4)에 명시된 바와 같이, 2024년부터 2025년까지 마이클 씨의 연금 가치 변동액이 증가한 주된 이유는 다음과 같습니다. (1) 마이클 씨가 회장 겸 최고경영자(CEO)로서 맡게 된 새로운 직무를 반영한 급여 조정으로 인해, 급여 산정식에 따른 5년간의 최종 평균 소득이 증가한 점, 그리고 (2) 마이클 씨가 2025년에 만 55세가 됨에 따라, 2003년 이후 근속 기간에 대해 지급될 보조 조기 퇴직 급여의 현재 가치가 일회성으로 증가했습니다. 이는 해당 연령에 도달하면 Pe 규정에 따라 62세부터 적용되는 급여가 보험수리학적으로 감액되기 때문입니다 [...]”원문The increase in Mr. Michael’s change in pension value from 2024 to 2025, as shown in footnote (4), is primarily due to the following: (1) Mr. Michael’s pay adjustments in recognition of his new responsibilities as Chairman and CEO, which resulted in an increase in his 5-year final average earnings under the benefit formulas, and (2) Mr. Michael turning age 55 in 2025, which resulted in a one-time increase in the present value of his subsidized early retirement benefits payable for service after 2003, since upon reaching that milestone his benefit is actuarially reduced from age 62 under the Pe [...]
Proxy (verbatim): “Employees who retire from AbbVie prior to their normal retirement age may receive subsidized early retirement benefits. Employees hired after 2003 are eligible for early retirement at age 55 with 10 years of service. Employees hired before 2004 are eligible for early retirement at age 50 with 10 years of service or age 55 if the employee’s age plus years of benefit service total 70 or more. Mr. Michael, Mr. Reents, Dr. Saleki-Gerhardt, Mr. Stewart, and Dr. Thakkar are eligible for early retirement benefits under the plan.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“AbbVie에서 정년 퇴직 연령 이전에 퇴직하는 직원은 보조금을 받는 조기 퇴직 급여를 받을 수 있습니다. 2003년 이후 입사한 직원은 근속 기간 10년 이상인 경우 만 55세에 조기 퇴직 자격을 얻습니다. 2004년 이전 입사 직원은 근속 기간 10년 이상인 경우 만 50세에, 또는 직원의 연령과 연금 수령 자격 기간을 합산하여 70 이상이 되는 경우 만 55세에 조기 퇴직 자격을 얻습니다. 마이클 씨, 렌츠 씨, 살레키-게르하르트 박사, 스튜어트 씨, 타카르 박사는 이 제도에 따라 조기 퇴직 급여를 받을 자격이 있습니다.”원문Employees who retire from AbbVie prior to their normal retirement age may receive subsidized early retirement benefits. Employees hired after 2003 are eligible for early retirement at age 55 with 10 years of service. Employees hired before 2004 are eligible for early retirement at age 50 with 10 years of service or age 55 if the employee’s age plus years of benefit service total 70 or more. Mr. Michael, Mr. Reents, Dr. Saleki-Gerhardt, Mr. Stewart, and Dr. Thakkar are eligible for early retirement benefits under the plan.
Proxy (verbatim): “● The Supplemental Pension Plan provides early retirement benefits similar to those provided under the Pension Plan. The benefits provided to NEOs under the Supplemental Pension Plan are not, however, reduced for the period between age 60 and age 62, unless the benefit is being actuarially reduced from age 65. Mr. Michael, Mr. Reents, Dr. Saleki-Gerhardt, Mr. Stewart, and Dr. Thakkar are eligible for early retirement benefits under the plan.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“● 보충 연금 제도는 연금 제도에서 제공하는 것과 유사한 조기 퇴직 급여를 제공합니다. 다만, 보충 연금 제도에 따라 NEO에게 지급되는 급여는 65세부터 보험수리학적 감액이 적용되지 않는 한, 60세부터 62세 사이의 기간 동안 감액되지 않습니다. 마이클 씨, 리엔츠 씨, 살레키-게르하르트 박사, 스튜어트 씨 및 타카르 박사는 이 제도에 따라 조기 퇴직 급여를 받을 자격이 있습니다.”원문● The Supplemental Pension Plan provides early retirement benefits similar to those provided under the Pension Plan. The benefits provided to NEOs under the Supplemental Pension Plan are not, however, reduced for the period between age 60 and age 62, unless the benefit is being actuarially reduced from age 65. Mr. Michael, Mr. Reents, Dr. Saleki-Gerhardt, Mr. Stewart, and Dr. Thakkar are eligible for early retirement benefits under the plan.
Proxy (verbatim): “(1) In accordance with Securities and Exchange Commission (SEC) rules, the amounts in this column represent the aggregate grant date fair value of the awards determined in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. AbbVie generally determines the grant date fair value of stock awards by multiplying the number of shares granted by the average of the high and low market prices of one share of AbbVie common stock on the award grant date. The grant date fair value of performance shares and performance-vested restricted stock units [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“(1) 미국 증권거래위원회(SEC) 규정에 따라, 이 열에 기재된 금액은 재무회계기준위원회(FASB)의 회계기준 코드화(ASC) 주제 718에 따라 산정된 보상권의 부여일 공정가치 총액을 나타냅니다. 애브비(AbbVie)는 일반적으로 부여일 공정가치를 산정할 때, 부여된 주식 수에 부여일 기준 애브비 보통주 1주당 최고가와 최저가의 평균가를 곱하는 방식으로 계산합니다. 성과주(performance shares) 및 성과 기반 제한주식단위(restricted stock units)의 부여일 공정가치는 [...]”원문(1) In accordance with Securities and Exchange Commission (SEC) rules, the amounts in this column represent the aggregate grant date fair value of the awards determined in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. AbbVie generally determines the grant date fair value of stock awards by multiplying the number of shares granted by the average of the high and low market prices of one share of AbbVie common stock on the award grant date. The grant date fair value of performance shares and performance-vested restricted stock units [...]
Proxy (verbatim): “R. Michael: $273,824 / $3,402 / $119,233; S. Reents: $95,464 / $31,435 / $90,112; J. Stewart: $152,820 / $23,084 / $277,907; A. Saleki-Gerhardt: $134,069 / $76,048 / $190,794; and R. Thakkar: $66,982.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“R. 마이클: 273,824달러 / 3,402달러 / 119,233달러; S. 렌츠: 95,464달러 / 31,435달러 / 90,112달러; J. 스튜어트: $152,820 / $23,084 / $277,907; A. 살레키-게르하르트: 134,069달러 / 76,048달러 / 190,794달러; 그리고 R. 타카르: 66,982달러.”원문R. Michael: $273,824 / $3,402 / $119,233; S. Reents: $95,464 / $31,435 / $90,112; J. Stewart: $152,820 / $23,084 / $277,907; A. Saleki-Gerhardt: $134,069 / $76,048 / $190,794; and R. Thakkar: $66,982.
Proxy (verbatim): “R. Michael: $7,873,176 / $1,669,967 / $2,776,666; S. Reents: $2,363,834 / $1,479,025 / $1,627,895; J. Stewart: $2,629,286 / $1,682,840 / $4,918,891; A. Saleki-Gerhardt: $620,095 / $(329,624) / $1,462,884; and R. Thakkar: $1,349,733.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“R. 마이클: 7,873,176달러 / 1,669,967달러 / 2,776,666달러; S. 렌츠: 2,363,834달러 / 1,479,025달러 / 1,627,895달러; J. 스튜어트: 2,629,286달러 / 1,682,840달러 / 4,918,891달러; A. 살레키-게르하르트: 620,095달러 / (329,624)달러 / 1,462,884달러; 그리고 R. 타카르: 1,349,733달러.”원문R. Michael: $7,873,176 / $1,669,967 / $2,776,666; S. Reents: $2,363,834 / $1,479,025 / $1,627,895; J. Stewart: $2,629,286 / $1,682,840 / $4,918,891; A. Saleki-Gerhardt: $620,095 / $(329,624) / $1,462,884; and R. Thakkar: $1,349,733.
Proxy (verbatim): “R. Michael: $500,081 / $335,617 / $123,213; S. Reents: $543,581 / $500,198 / $294,882; J. Stewart: $960,131 / $939,164 / $594,880; and A. Saleki-Gerhardt: $1,024,714 / $1,052,397 / $707,787.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“R. 마이클: 500,081달러 / 335,617달러 / 123,213달러; S. 렌츠: 543,581달러 / 500,198달러 / 294,882달러; J. 스튜어트: 960,131달러 / 939,164달러 / 594,880달러; A. 살레키-게르하르트: 1,024,714달러 / 1,052,397달러 / 707,787달러.”원문R. Michael: $500,081 / $335,617 / $123,213; S. Reents: $543,581 / $500,198 / $294,882; J. Stewart: $960,131 / $939,164 / $594,880; and A. Saleki-Gerhardt: $1,024,714 / $1,052,397 / $707,787.
Proxy (verbatim): “R. Michael: $169,220; S. Reents: $327,713; J. Stewart: $631,388; and A. Saleki-Gerhardt: $725,085.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“R. 마이클: 169,220달러; S. 린츠: 327,713달러; J. 스튜어트: 631,388달러; A. 살레키-게르하르트: 725,085달러.”원문R. Michael: $169,220; S. Reents: $327,713; J. Stewart: $631,388; and A. Saleki-Gerhardt: $725,085.
Proxy (verbatim): “R. Michael: $85,000; S. Reents: $56,206; J. Stewart: $65,786; A. Saleki-Gerhardt: $52,629; and R. Thakkar: $17,500.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“R. 마이클: 85,000달러; S. 렌츠: 56,206달러; J. 스튜어트: 65,786달러; A. 살레키-게르하르트: 52,629달러; R. 타카르: 17,500달러.”원문R. Michael: $85,000; S. Reents: $56,206; J. Stewart: $65,786; A. Saleki-Gerhardt: $52,629; and R. Thakkar: $17,500.
Proxy (verbatim): “The totals shown in the table include the cost of providing a corporate automobile less the amount reimbursed by the NEO: R. Michael: $32,262; S. Reents: $35,166; J. Stewart: $23,598; A. Saleki-Gerhardt: $25,992; and R. Thakkar: $5,993. AbbVie imputes income to the NEO, if required, and the NEO pays taxes in accordance with tax regulations without gross-ups.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“표에 표시된 총액에는 회사 차량 제공 비용이 포함되어 있으며, 여기에서 최고경영진(NEO)이 상환한 금액을 차감한 금액입니다: R. Michael: 32,262달러; S. Reents: 35,166달러; J. 스튜어트: $23,598; A. 살레키-게르하르트: $25,992; R. 타카르: $5,993. AbbVie는 필요한 경우 NEO에게 소득을 귀속시키며, NEO는 세법 규정에 따라 세전 보정을 하지 않고 세금을 납부합니다.”원문The totals shown in the table include the cost of providing a corporate automobile less the amount reimbursed by the NEO: R. Michael: $32,262; S. Reents: $35,166; J. Stewart: $23,598; A. Saleki-Gerhardt: $25,992; and R. Thakkar: $5,993. AbbVie imputes income to the NEO, if required, and the NEO pays taxes in accordance with tax regulations without gross-ups.
Proxy (verbatim): “The totals shown in the table include a financial planning services allowance for each NEO: R. Michael: $10,000; S. Reents: $10,000; J. Stewart: $10,000; A. Saleki-Gerhardt: $10,000; and R. Thakkar: $10,000. AbbVie imputes income to the NEO, if required, and the NEO pays taxes in accordance with tax regulations without gross-ups.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“표에 표시된 총액에는 각 NEO에 대한 재무 계획 서비스 수당이 포함되어 있습니다: R. Michael: 10,000달러; S. Reents: 10,000달러; J. 스튜어트: 10,000달러; A. 살레키-게르하르트: 10,000달러; R. 타카르: 10,000달러. AbbVie는 필요한 경우 NEO에게 소득을 귀속시키며, NEO는 총액 조정 없이 세법에 따라 세금을 납부합니다.”원문The totals shown in the table include a financial planning services allowance for each NEO: R. Michael: $10,000; S. Reents: $10,000; J. Stewart: $10,000; A. Saleki-Gerhardt: $10,000; and R. Thakkar: $10,000. AbbVie imputes income to the NEO, if required, and the NEO pays taxes in accordance with tax regulations without gross-ups.
Proxy (verbatim): “The totals shown in the table include the following costs for non-business-related air travel and services less the amount reimbursed by the NEO: R. Michael: $212,609; S. Reents: $41,403; and R. Thakkar: $23,966. AbbVie determines the incremental cost for flights based on the direct cost to AbbVie, including fuel costs, parking, handling and landing fees, catering, travel fees, and other miscellaneous direct costs. AbbVie imputes income to the NEO, if required, and the NEO pays taxes in accordance with tax regulations without gross-ups.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“표에 표시된 총액에는 업무와 무관한 항공 여행 및 서비스에 대한 다음 비용이 포함되어 있으며, NEO가 상환한 금액을 차감한 금액입니다: R. Michael: 212,609달러; S. Reents: 41,403달러; R. Thakkar: 23,966달러. 애브비(AbbVie)는 연료비, 주차비, 취급 및 착륙료, 기내식비, 여행비 및 기타 제반 직접 비용을 포함하여 애브비에 발생하는 직접 비용을 기준으로 항공편에 대한 증분 비용을 산정합니다. 필요한 경우, 애브비는 NEO에게 소득을 귀속시키며, NEO는 총액 조정 없이 세법에 따라 세금을 납부합니다.”원문The totals shown in the table include the following costs for non-business-related air travel and services less the amount reimbursed by the NEO: R. Michael: $212,609; S. Reents: $41,403; and R. Thakkar: $23,966. AbbVie determines the incremental cost for flights based on the direct cost to AbbVie, including fuel costs, parking, handling and landing fees, catering, travel fees, and other miscellaneous direct costs. AbbVie imputes income to the NEO, if required, and the NEO pays taxes in accordance with tax regulations without gross-ups.
Proxy (verbatim): “As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of our median employee and the annual total compensation of Robert Michael, our CEO. The pay ratio included in this information is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K. The ratio of Mr. Michael’s annual total compensation for 2025, as reported in the Summary Compensation Table of this proxy statement, to the median [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“도드-프랭크 월스트리트 개혁 및 소비자 보호법 제953(b)조 및 규정 S-K 제402(u)항에 따라, 당사는 당사 직원 중 중앙값에 해당하는 직원의 연간 총보상과 당사 CEO인 로버트 마이클 씨의 연간 총보상 간의 관계에 관한 다음 정보를 제공합니다. 본 정보에 포함된 보상 비율은 규정 S-K 제402(u)항에 부합하는 방식으로 산출된 합리적인 추정치입니다. 본 위임장 설명서의 ‘보상 요약표’에 보고된 마이클 씨의 2025년 연간 총보상과 중앙값 [...]의 비율은”원문As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of our median employee and the annual total compensation of Robert Michael, our CEO. The pay ratio included in this information is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K. The ratio of Mr. Michael’s annual total compensation for 2025, as reported in the Summary Compensation Table of this proxy statement, to the median [...]
Proxy (verbatim): “The dollar amounts reported are the total compensation reported for Mr. Michael (PEO) for fiscal years 2024 and 2025, and Mr. Gonzalez (former PEO, who served as PEO until July 1, 2024) for fiscal years 2021, 2022, 2023 and 2024 in the “Total” column of the Summary Compensation Table.”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“보고된 달러 금액은 2024 회계연도 및 2025 회계연도에 대해 마이클 씨(최고경영자)에게, 그리고 2021 회계연도, 2022 회계연도, 2023년 및 2024년 회계연도에 대해 ‘보상 요약표’의 ‘총액’ 열에 기재된 보상 총액입니다.”원문The dollar amounts reported are the total compensation reported for Mr. Michael (PEO) for fiscal years 2024 and 2025, and Mr. Gonzalez (former PEO, who served as PEO until July 1, 2024) for fiscal years 2021, 2022, 2023 and 2024 in the “Total” column of the Summary Compensation Table.
Proxy (verbatim): “The dollar amounts reported represent the “compensation actually paid” to Mr. Michael for fiscal years 2024 and 2025, and to Mr. Gonzalez (former PEO) for fiscal years 2021, 2022 and 2023, and 2024, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Michael or Mr. Gonzalez during such fiscal years and are based on valuation assumptions required by the SEC, which are unlikely to reflect actual amounts realized at vesting or exercise (as applicable). In accordance with the requirements of Item [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“보고된 달러 금액은 2024 회계연도 및 2025 회계연도에 마이클 씨에게, 그리고 2021, 2022년, 2023년 및 2024년에 각각 마이클 씨와 곤잘레스 씨(전직 PEO)에게 지급된 “실제 지급된 보상”을 나타내며, 이는 규정 S-K 제402(v)항에 따라 산정된 금액입니다. 이 금액은 해당 회계연도 동안 마이클 씨나 곤잘레스 씨가 실제로 획득하거나 지급받은 보상액을 반영한 것이 아니며, SEC가 요구하는 평가 가정을 바탕으로 한 것으로, 이는 귀속 또는 행사(해당되는 경우) 시점에 실현된 실제 금액을 반영하지 않을 가능성이 높습니다. 항목 [...]의 요건에 따라”원문The dollar amounts reported represent the “compensation actually paid” to Mr. Michael for fiscal years 2024 and 2025, and to Mr. Gonzalez (former PEO) for fiscal years 2021, 2022 and 2023, and 2024, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Michael or Mr. Gonzalez during such fiscal years and are based on valuation assumptions required by the SEC, which are unlikely to reflect actual amounts realized at vesting or exercise (as applicable). In accordance with the requirements of Item [...]
Proxy (verbatim): “(1) The amount reflected in the “Stock Award” and “Option Award” columns of the Summary Compensation Table with respect to Mr. Michael and Mr. Gonzalez has been deducted from the Summary Compensation Table Total and substituted with an equity award value for each year calculated by adding or subtracting, as applicable, the following: (i) the year-end fair value of any equity awards granted in the applicable fiscal year that are outstanding and unvested as of the”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“(1) 마이클 씨 및 곤잘레스 씨와 관련하여 ‘보상 요약표’의 “주식 보상” 및 “스톡옵션 보상” 열에 반영된 금액은 보상 요약표 총액에서 차감되었으며, 대신 다음 항목을 해당 연도에 따라 가감하여 산출한 각 연도의 지분 보상 가치가 대체되어 기재되었습니다: (i) 해당 회계연도에 부여되어 해당 시점(연말)까지 미행사 및 미행사가격 충족 상태인 모든 주식 보상 권리의 연말 공정가치”원문(1) The amount reflected in the “Stock Award” and “Option Award” columns of the Summary Compensation Table with respect to Mr. Michael and Mr. Gonzalez has been deducted from the Summary Compensation Table Total and substituted with an equity award value for each year calculated by adding or subtracting, as applicable, the following: (i) the year-end fair value of any equity awards granted in the applicable fiscal year that are outstanding and unvested as of the
Proxy (verbatim): “The amounts in the following table represent each of the amounts deducted and added to the equity award values for Mr. Michael for the 2025 fiscal year for purposes of computing the “compensation actually paid” amount appearing in column (b) of the pay versus performance table:”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“다음 표에 기재된 금액은 성과 대비 보상 표의 (b) 열에 표시된 “실제 지급된 보상” 금액을 산정하기 위해, 2025 회계연도 마이클 씨의 지분 보상 가치에서 공제되거나 가산된 각 금액을 나타냅니다:”원문The amounts in the following table represent each of the amounts deducted and added to the equity award values for Mr. Michael for the 2025 fiscal year for purposes of computing the “compensation actually paid” amount appearing in column (b) of the pay versus performance table:
Proxy (verbatim): “(2) The pension benefit value reported in the “Change in Pension Value and Non-qualified Deferred Compensation Earnings” column of the Summary Compensation Table for the 2025 fiscal year is adjusted to account for the aggregate of two components: (i) the actuarially determined service cost for services rendered by Mr. Michael during 2025 (the “service cost”); and (ii) the entire cost of benefits granted in a plan amendment during 2025 that are attributed by the benefit formula to services rendered in periods prior to the plan amendment (the “prior service cost”), in each case, calculated in ac [...]”[DEF 14A]
[DEF 14A]위임장 원문: 자동 번역(참고용)“(2) 2025 회계연도 보상 요약표의 “연금 가치 및 비적격 이연 보상 수익의 변동” 열에 보고된 연금 급여 가치는 다음 두 가지 구성 요소의 합계를 반영하여 조정됩니다. (i) 2025년 동안 마이클 씨가 제공한 근무에 대해 보험수리적으로 산정된 근무 비용(“근무 비용”); 그리고 (ii) 2025년 중 계획 개정 시 부여된 급여 중, 급여 산정식에 따라 계획 개정 이전 기간 동안 제공된 근속 기간에 귀속되는 급여 비용 전액(이하 “이전 근속 비용”)으로, 각 항목은 모두 [...]에 따라 계산된 금액입니다.”원문(2) The pension benefit value reported in the “Change in Pension Value and Non-qualified Deferred Compensation Earnings” column of the Summary Compensation Table for the 2025 fiscal year is adjusted to account for the aggregate of two components: (i) the actuarially determined service cost for services rendered by Mr. Michael during 2025 (the “service cost”); and (ii) the entire cost of benefits granted in a plan amendment during 2025 that are attributed by the benefit formula to services rendered in periods prior to the plan amendment (the “prior service cost”), in each case, calculated in ac [...]
Nothing on file in the window.기간 내 해당 공시 없음.
Nothing on file in the window.기간 내 해당 공시 없음.
| Filed제출일 | Document문서 | Link링크 |
|---|---|---|
| 2026-02-20 | Form 4 | sec.gov |
| 2026-03-03 | Form 4 | sec.gov |
| 2026-03-23 | DEF 14A | sec.gov |
Not used, by policy: news articles, LinkedIn, social media. Quotes are reproduced exactly as filed.원칙상 사용하지 않은 것: 뉴스 기사, LinkedIn, 소셜 미디어. 인용문은 공시 원문 그대로입니다.